E-Mail
MINNEAPOLIS - A new study shows that intense immunosuppression followed by a hematopoietic stem cell transplant may prevent disability associated with multiple sclerosis (MS) from getting worse in 71% of people with relapsing-remitting MS for up to 10 years after the treatment. The research is published in the January 20, 2021, online issue of
Neurology®, the medical journal of the American Academy of Neurology. The study also found that in some people their disability improved over 10 years after treatment. Additionally, more than half of the people with the secondary progressive form of MS experienced no worsening of their symptoms 10 years after a transplant.
By examining fruit flies brain activity and behavior, the researchers found that deep sleep has an ancient, restorative power to clear waste from the brain. This waste potentially includes toxic proteins that may lead to neurodegenerative disease.
Early life experiences can have an outsized effect on brain development and neurobiological health. New research is showing that those effects can be passed down to subsequent generations, reporting that the infant children of mothers who had experienced childhood emotional neglect displayed altered brain circuitry involved in fear responses and anxiety.
E-Mail
Philadelphia, January 19, 2021 - Early life experiences can have an outsized effect on brain development and neurobiological health. New research is showing that those effects can be passed down to subsequent generations, reporting that the infant children of mothers who had experienced childhood emotional neglect displayed altered brain circuitry involved in fear responses and anxiety.
The study appears in These results show that our brain development is not only shaped by what happens in our own life, but is also impacted by things that happened to our parents before we were even conceived, said lead author of the study, Cassandra Hendrix, PhD, Department of Pyschology, Emory University, Atlanta, GA, USA.
Vancouver, British Columbia (Newsfile Corp. - January 19, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) (OTC Pink: ENTBF) ("Entheon" or the "Company"), a biotechnology company focused on